Condition Directory

Head and Neck Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Head and Neck Cancer. Browse Head and Neck Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 18, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

360

Shown on this page

Current sort

How Head and Neck Cancer studies are organized in the registry

Most records use the formal phrase “squamous cell carcinoma of the head and neck” or the abbreviation HNSCC, and site-specific terms like “oropharyngeal” mark distinct subsets. HPV status is a common population-defining label in this portfolio, and combined-modality studies (radiation plus systemic therapy) are frequent.

Terms that often appear in related listings

HNSCC oropharyngeal HPV-positive chemoradiation

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 169–180 of 360 matching trials for Head and Neck Cancer.

Live ClinicalTrials.gov results.

Active filters: "chemoradiation" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7
Interventions: Carboplatin, Cisplatin, Fluorouracil, Hydroxyurea, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Radiation Therapy, Veliparib; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 5
States / cities: Chicago, Illinois • Evanston, Illinois • St Louis, Missouri + 1 more

Conditions: Chemoradiotherapy-Induced Severe Oral Mucositis
Interventions: Clonidine HCl Mucoadhesive Buccal Tablet, Placebo Mucoadhesive Buccal Tablet; Drug
Lead sponsor: Monopar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 48
States / cities: Little Rock, Arkansas • Fountain Valley, California • Long Beach, California + 42 more

Conditions: Head and Neck Cancer
Interventions: ZD 1839 500mg; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Head and Neck Carcinoma, Head and Neck Lymph Node, Head and Neck Squamous Cell Carcinoma, Laryngeal Neoplasm, Radiation Therapy Recipient
Interventions: Photoacoustic Imaging, Transcutaneous Acupoint Electrical Stimulation; Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Head and Neck Cancer
Interventions: BMX-001, Radiation Therapy, Cisplatin; Drug · Radiation
Lead sponsor: BioMimetix JV, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: San Francisco, California • Gainesville, Florida • Omaha, Nebraska + 1 more

Conditions: Mucositis
Interventions: Low Level Laser Therapy; Device
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Caregiver, Head and Neck Carcinoma, Lung Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Lung Carcinoma, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: Mucositis
Interventions: SBI, Placebo; Dietary Supplement
Lead sponsor: MercyOne Des Moines Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Des Moines, Iowa

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: Nivolumab, Cisplatin, Cetuximab, IMRT; Drug · Radiation
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 11
States / cities: Palo Alto, California • Orlando, Florida • Atlanta, Georgia + 8 more

Conditions: Squamous Cell Carcinoma, Oropharynx Cancer
Interventions: Intensity modulated radiotherapy (IMRT), PET-MRI; Radiation · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis
Interventions: SGX942, Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 32
States / cities: Tucson, Arizona • Loma Linda, California • Pomona, California + 29 more

About this Head and Neck Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Head and Neck Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Head and Neck Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Head and Neck Cancer clinical trials

How Head and Neck Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer

A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

Low-Level Laser Therapy for Prevention of Oral Mucositis

Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers

Serum-derived Bovine Immunoglobulin Effect on Mucositis

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

About this Head and Neck Cancer clinical trials directory page